[go: up one dir, main page]

EP0850067A4 - METHOD FOR CANCER TREATMENT USING 6- (3- (1-ADAMANTYL) -4-HYDROXYPHENYL) 2 NAPHTALINE CARBONIC ACID - Google Patents

METHOD FOR CANCER TREATMENT USING 6- (3- (1-ADAMANTYL) -4-HYDROXYPHENYL) 2 NAPHTALINE CARBONIC ACID

Info

Publication number
EP0850067A4
EP0850067A4 EP96924519A EP96924519A EP0850067A4 EP 0850067 A4 EP0850067 A4 EP 0850067A4 EP 96924519 A EP96924519 A EP 96924519A EP 96924519 A EP96924519 A EP 96924519A EP 0850067 A4 EP0850067 A4 EP 0850067A4
Authority
EP
European Patent Office
Prior art keywords
naphtaline
adamantyl
hydroxyphenyl
carbonic acid
cancer treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP96924519A
Other languages
German (de)
French (fr)
Other versions
EP0850067A1 (en
Inventor
Joseph A Fontana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Centre International de Recherches Dermatologiques Galderma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre International de Recherches Dermatologiques Galderma filed Critical Centre International de Recherches Dermatologiques Galderma
Publication of EP0850067A1 publication Critical patent/EP0850067A1/en
Publication of EP0850067A4 publication Critical patent/EP0850067A4/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EP96924519A 1995-07-17 1996-07-17 METHOD FOR CANCER TREATMENT USING 6- (3- (1-ADAMANTYL) -4-HYDROXYPHENYL) 2 NAPHTALINE CARBONIC ACID Ceased EP0850067A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US601465 1990-10-23
US146595P 1995-07-17 1995-07-17
PCT/US1996/011736 WO1997003682A1 (en) 1995-07-17 1996-07-17 Method for treating cancers using 6-[3-[1-adamantyl]-4-hydroxyphenyl]

Publications (2)

Publication Number Publication Date
EP0850067A1 EP0850067A1 (en) 1998-07-01
EP0850067A4 true EP0850067A4 (en) 1999-12-15

Family

ID=21696159

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96924519A Ceased EP0850067A4 (en) 1995-07-17 1996-07-17 METHOD FOR CANCER TREATMENT USING 6- (3- (1-ADAMANTYL) -4-HYDROXYPHENYL) 2 NAPHTALINE CARBONIC ACID

Country Status (5)

Country Link
EP (1) EP0850067A4 (en)
JP (1) JP2000506489A (en)
AU (1) AU701790B2 (en)
CA (1) CA2223489A1 (en)
WO (1) WO1997003682A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2739557B1 (en) 1995-10-09 1997-11-14 Cird Galderma USE OF A RAR-GAMMA SPECIFIC AGONIST LIGAND
US6462064B1 (en) 1996-07-08 2002-10-08 Galderma Research & Development S.N.C. Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents, especially for cervical cancers and dysplasias
NZ333800A (en) * 1996-07-08 2000-08-25 Galderma Res & Dev Apoptosis inducing adamantyl derivatives and pharmaceutical uses
UA74344C2 (en) 1999-08-31 2005-12-15 Максіа Фармасьютікалз, Інк. Benzylidenethiazolidinedions and analogues thereof and use in the treatment of diabetes
MXPA03008117A (en) 2001-03-07 2004-11-12 Incyte San Diego Inc Heterocyclic derivatives for the treatment of cancer and other proliferative diseases.
AU2002254171A2 (en) 2001-03-08 2002-09-24 Incyte San Diego, Inc. RXR activating molecules
DE10255861A1 (en) * 2002-11-29 2004-06-17 Axxima Pharmaceuticals Ag Preventing or treating hepatitis C virus infection comprises administering an agent that inhibits or stimulates the activity or production of human gastrointestinal glutathione peroxidase
KR100453877B1 (en) 2001-07-26 2004-10-20 메덱스젠 주식회사 METHOD OF MANUFACTURING Ig-FUSION PROTEINS BY CONCATAMERIZATION, TNFR/Fc FUSION PROTEINS MANUFACTURED BY THE METHOD, DNA CODING THE PROTEINS, VECTORS INCLUDING THE DNA, AND CELLS TRANSFORMED BY THE VECTOR
AU2002352706A1 (en) 2001-11-15 2003-06-10 Maxia Pharmaceuticals, Inc. N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders, cancer, and other diseases
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
US7102000B2 (en) 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
JP2006514094A (en) * 2002-11-29 2006-04-27 ゲーペーツェー バイオテック アクチェンゲゼルシャフト Formulations useful for hepatitis C virus infection
US20090117203A1 (en) * 2006-03-23 2009-05-07 Tmrc Co., Ltd. Kit for cancer treatment and pharmaceutical composition for cancer treatment
JP5054006B2 (en) * 2006-06-23 2012-10-24 ロート製薬株式会社 Composition having hyaluronic acid production promoting ability
EP3301085A1 (en) 2016-09-29 2018-04-04 Biogem S.Ca.R.L. Retinoid derivatives with antitumor activity
WO2022229017A1 (en) 2021-04-27 2022-11-03 Biogem S.C.A R.L. Adamantyl retinoid derivative with anticancer activity

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU85849A1 (en) * 1985-04-11 1986-11-05 Cird BENZONAPHTHALENIC DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION IN THE PHARMACEUTICAL AND COSMETIC FIELDS

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BOEHM M F ET AL: "DESIGN AND SYNTHESIS OF POTENT RETINOID X RECEPTOR SELECTIVE LIGANDS THAT INDUCE APOPTOSIS IN LEUKEMIA CELLS", JOURNAL OF MEDICINAL CHEMISTRY, vol. 38, no. 16, 4 August 1995 (1995-08-04), pages 3146 - 3155, XP000615461, ISSN: 0022-2623 *
CORBEIL J ET AL: "ANTIPROLIFERATIVE EFFECT OF RETINOID COMPOUNDS ON KAPOSI'S SARCOMA CELLS", JOURNAL OF CLINICAL INVESTIGATION, vol. 93, no. 5, 1 May 1994 (1994-05-01), pages 1981 - 1986, XP000646558, ISSN: 0021-9738 *
SCHADENDORF, D. ET AL.: "Retinoic acid receptor-gamma-selective retinoids exert antiproliverative effects on human melanoma cell growth in vitro", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 5, no. 6, 1994, pages 1325 - 1331, XP000600684 *
See also references of WO9703682A1 *
SHAO Z -M ET AL: "P53 INDEPENDENT G0/G1 ARREST AND APOPTOSIS INDUCED BY A NOVEL RETINOID IN HUMAN BREAST CANCER CELLS", ONCOGENE, vol. 11, no. 3, 3 August 1995 (1995-08-03), pages 493 - 504, XP000575582, ISSN: 0950-9232 *

Also Published As

Publication number Publication date
EP0850067A1 (en) 1998-07-01
CA2223489A1 (en) 1997-02-06
WO1997003682A1 (en) 1997-02-06
JP2000506489A (en) 2000-05-30
AU701790B2 (en) 1999-02-04
AU6494996A (en) 1997-02-18

Similar Documents

Publication Publication Date Title
DE69516188D1 (en) METHOD FOR PRODUCING THEREPHTHALIC ACID
DE59603155D1 (en) METHOD FOR PRODUCING HYDROTALCITES
EP0850067A4 (en) METHOD FOR CANCER TREATMENT USING 6- (3- (1-ADAMANTYL) -4-HYDROXYPHENYL) 2 NAPHTALINE CARBONIC ACID
ATE243211T1 (en) METHOD FOR PRODUCING DIHALOGENAZOLOPYRIMIDINES
DE69620461D1 (en) METHOD FOR PRODUCING 1,1,1,3,3, -PENTAFLUOROPROPANES
DE69310749D1 (en) METHOD FOR PRODUCING VITAMIN-ENRICHED CEREAL
DE59604922D1 (en) METHOD FOR PRODUCING POLYALCOHOLES
DE69618476D1 (en) METHOD FOR PRODUCING 1,1,1,3,3-PENTAFLUORPROPANE
DE69604277D1 (en) METHOD FOR PRODUCING NOOT CATALON
DE69626119D1 (en) METHOD FOR PRODUCING 3- (METHYLTHIO) PROPANOL
DE69304295D1 (en) METHOD FOR PRODUCING 2-HYDROXY-4-METHYLTHIOBUTANIC ACID
ATE212380T1 (en) METHOD FOR PRODUCING NICOTINIC ACID AMIDE
DE69603502D1 (en) METHOD FOR PRODUCING 1,3-PROPANEDOL
ATE303134T1 (en) METHOD FOR PRODUCING FLAVANO-LIGNAN PREPARATIONS
DE59601604D1 (en) METHOD FOR PRODUCING N-ARYL- AND N-HETARYLHYDROXYLAMINES
ATE229021T1 (en) METHOD FOR PRODUCING IMIDAZOQUINAZOLINONE DERIVATIVES
DE69628203D1 (en) METHOD FOR PRODUCING PHENYLIMIDAZOLINE DERIVATIVES
DE59407708D1 (en) METHOD FOR PRODUCING HOMO AND COPOLYMERISATS FROM ALK-1-ENEN
DE69109964D1 (en) Method and device for producing brine.
ATE309230T1 (en) METHOD FOR PRODUCING 2-CHLORTHIAZOLE DERIVATIVES
ATE203046T1 (en) METHOD FOR PRODUCING PIGMENTS
DE69431759D1 (en) METHOD FOR PRODUCING N-METHYL-3- (1-METHYL-4-PIPERIDINYL) -1H-INDOL-5-ETHANESULFONAMIDE
ATE207900T1 (en) METHOD FOR PRODUCING ROPIVACAINEHYDROCHLORIDE MONOHYDRATE
DE69432333D1 (en) Water treatment method using 5-allyldibenzosuberenol
DE69616322D1 (en) METHOD FOR PRODUCING 3-ISOCHROMANONES

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980202

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19991104

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20001005

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/79 A, 7A 61P 35/02 B, 7A 61P 35/00 B

RTI1 Title (correction)

Free format text: METHOD FOR TREATING BREAST CANCER AND LEUKEMIA USING 6- (3-(1-ADAMANTYL)-4-HYDROXYPHENYL)-2-NAPHTHALENE CARBOXYLIC ACID

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/79 A, 7A 61P 35/02 B, 7A 61P 35/00 B

RTI1 Title (correction)

Free format text: 6- (3-(1-ADAMANTYL)-4-HYDROXYPHENYL)-2-NAPHTHALENE CARBOXYLIC ACID AGAINST BREAST CANCER AND LEUKEMIA

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/79 A, 7A 61P 35/02 B, 7A 61P 35/00 B

RTI1 Title (correction)

Free format text: 6- (3-(1-ADAMANTYL)-4-HYDROXYPHENYL)-2-NAPHTHALENE CARBOXYLIC ACID AGAINST BREAST CANCER AND LEUKEMIA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20020429

RTI1 Title (correction)

Free format text: 6- ??3-??1-ADAMANTYL -4-HYDROXYPHENYL -2-NAPHTHALENE CARBOXYLIC ACID AGAINST BREAST CANCER AND LEUKEMIA